[Follow-up studies in XXXX rheumatica and @entity226 ].

@entity1 @entity226 @entity228 @entity2760
OBJECTIVE: To analyze the clinical course and duration of therapy in 28 @entity1 with @entity2760 rheumatica (PMR) and/or @entity226 ( @entity226 ) for identifying factors that influence prolonged steroid use and relapses. METHODS: 28 cases of PMR and/or @entity226 diagnosed from 1992 to 2001 were retrospectively studied in PUMC hospital. @entity1 were grouped according to the absence or presence of corticosteroid resistant and relapses. RESULTS: Of 28 @entity1 , 22 had pure PMR, 3 had both PMR and @entity226 and 3 had pure @entity226 . 15 @entity1 received corticosteroid therapy and 13 had both corticosteroid and immunosuppressor therapy. The median duration was (25.5 +/- 24.0) months. Increase of white blood cell level and higher baseline erythrocyte sedimentation rate (ESR) were significant risk factors associated with corticosteroid resistant (P < 0.01). Quicker reduction of @entity228 dose was associated with relapse (P < 0.05). CONCLUSIONS: @entity1 with increase of white blood cell level and higher baseline erythrocyte sedimentation rate (ESR) are more likely to be resistant to corticosteroid therapy. Quicker reduction in corticosteroid is more likely to relapse. Immunosuppressor therapy should be added to @entity1 who has corticosteroid resistant, and relapse or PMR associated with @entity226 .
